August 1, 2007Journal of Cardiovascular Medicine
Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design amd rationale
Key result
Colchicine will be evaluated against placebo in 240 patients with acute pericarditis to determine its effect on the recurrence rate at 18 months.
Why the study?
Does colchicine reduce the recurrence rate at 18 months in patients with acute pericarditis?
Population
240 patients with acute pericarditis
Comparison
Colchicine as adjunct to conventional therapy vs Placebo
Design
Other, randomized, double-blind
Follow-up
18 months
Authors
Discussion
Loading...
Member takes
Implication
This first RCT of colchicine in acute pericarditis will test recurrence prevention; delivers initial randomized evidence to guide practice.
Study Design
Type
RCT (n=240)
Blinding
double-blind
Randomization
randomized
Multicenter
Yes
Structured PICO
Does colchicine reduce the recurrence rate at 18 months in patients with acute pericarditis?
P
Population
240 patients with acute pericarditis to be enrolled and followed for 18 months.
I
Intervention
Colchicine as adjunct to conventional therapy
C
Comparator
Placebo
O
Outcome
Recurrence rate at 18 monthshard clinical
The ICAP trial will provide the first randomized, placebo-controlled evidence on the efficacy of early colchicine use for treating acute pericarditis and preventing recurrences.
Cite This Study
Imazio et al. (2007) conducted an RCT in acute pericarditis (n=240). Colchicine vs. Placebo was evaluated on recurrence rate at 18 months. Colchicine will be evaluated against placebo in 240 patients with acute pericarditis to determine its effect on the recurrence rate at 18 months.